Immunologically active phenotype is associated with response to PD-1/PD-L1 inhibitors in patients with advanced non-small cell lung cancer

Immunotherapy in immunologically active tumors may improve prognosis of non-small cell lung carcinomas (NSCLC). Our objective was to develop a reliable and stable scoring system for the identification of immunologically active HNSCC and to evaluate its association with response to immunotherapies. A Hot Oral Tumor (HOT) score was developed using data from The Cancer Genome Atlas in human-papillomavirus negative head and neck squamous cell carcinomas; it was computed in 92 patients with early stage NSCLC treated with surgery to evaluate the prognostic impact of the HOT score. In 92 patients with surgically treated NSCLC, gene expression profiles were generated using formalin-fixed paraffin embedded biopsies or surgically resected specimens collected prior to treatment initiation. Gene expression profiles were generated using HTG EdgeSeq technology and the Oncology Biomarker Panel (OBP). >>>Submitter states that raw data are currently unavailable. They are working with the sequencing company to retrieve the raw files<<<